- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00428012
Quality of Life Therapy for Adults With ESRD Awaiting Renal Transplantation
January 5, 2012 updated by: James Rodrigue, Beth Israel Deaconess Medical Center
The purpose of this study is to determine whether psychological intervention is effective in improving quality of life, mood, and relationships among adults with end-stage renal disease who are awaiting kidney transplantation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Despite known quality of life (QOL) deficits associated with end-stage renal disease (ESRD), there have been very few attempts to develop strategies to improve QOL in adults with ESRD awaiting renal transplantation.
The long-term goal of this research program is to better understand how QOL can be enhanced, to identify the mechanisms underlying QOL changes, to identify which patients benefit most from QOL intervention, and to determine whether QOL benefits can extend beyond transplantation.
The objective of this research is to determine the effectiveness, feasibility and applicability of Quality of Life Therapy (QOLT) in treating adults with ESRD awaiting renal transplantation.
In a recent small, single-center clinical trial, we demonstrated that QOLT can improve QOL, psychological functioning, and social intimacy in patients awaiting lung transplantation.
We now seek to examine whether this intervention can be effectively adapted and implemented with adults with ESRD who are awaiting renal transplantation.
The central hypothesis is that by targeting improvements in specific life domains, QOLT yields significant clinical benefits in QOL, psychological functioning, and the patient-caregiver relationship.
This hypothesis is being tested by pursuing three specific aims: 1) Determine the effectiveness of QOLT; 2) Examine the differential effectiveness of QOLT by race (White, African American); and 3) Assess the feasibility of a multisite R01 application.
Under the first aim, adults with ESRD awaiting renal transplantation are being randomized to receive QOLT, Supportive Therapy (ST), or Standard Care (SC).
Primary outcomes are changes in QOL, psychological functioning, and social intimacy at 1 and 12 weeks post-treatment.
Under the second aim, the relationship between race and intervention outcomes will be closely examined.
Under the third aim, attrition rates, reasons for attrition, therapist adherence to treatment protocols, and participant satisfaction ratings are being gathered to assess the need for protocol changes prior to developing a larger, multisite clinical trial R01 application.
This study is innovative because it is among the first to evaluate a theoretically-driven psychological intervention to specifically improve QOL in the context of ESRD and renal transplantation.
The research is significant because it is expected to advance and expand understanding of how QOL can be improved in patients with ESRD.
Study Type
Interventional
Enrollment (Actual)
65
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- The Transplant Center, Beth Israel Deaconess Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patients between 21 and 70 years of age
- Diagnosis of ESRD
- Wait-listed for deceased donor renal transplantation (primary transplant only)
- White or African American race
- Signed informed consent
- Primary caregiver identified as spouse or domestic partner
- Resides within 60 minutes of transplant center
Exclusion Criteria:
- Prior recipient of renal transplantation
- Prior recipient of other solid organ transplantation
- Wait-listed for combined kidney-pancreas transplantation
- Current substance abuse or dependency
- Currently hospitalized
- Current recipient of psychological intervention services
- Mental retardation
- Substantial cognitive impairment (score of 23 or less on the Mini-Mental State Examination)
- Communication difficulties (speech, hearing) so substantial that they would prevent patient from participating actively in one of the interventions (determined by transplant social worker)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard Care
|
|
Experimental: QOLT
Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions
|
8 weekly individual counseling sessions
|
Active Comparator: ST
Supportive Therapy (ST) 8 weekly individual counseling sessions
|
8 weekly individual counseling sessions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary: Scores on the following measures at 12 weeks post-intervention: Quality of Life Inventory, SF-36, KDQoL, CDC Activity Limitations Module, Hopkins Symptom Checklist, POMS, and Miller Social Intimacy Scale
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: James R. Rodrigue, PhD, Beth Israel Deaconess Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Primary Completion (Actual)
July 1, 2009
Study Completion (Actual)
April 1, 2011
Study Registration Dates
First Submitted
January 25, 2007
First Submitted That Met QC Criteria
January 25, 2007
First Posted (Estimate)
January 29, 2007
Study Record Updates
Last Update Posted (Estimate)
January 6, 2012
Last Update Submitted That Met QC Criteria
January 5, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R21 DK77322 (completed)
- R21DK077322 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End-stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted
-
Clinical Research Center for End Stage Renal Disease...Kyungpook National University Hospital; Medical Research Collaborating Center... and other collaboratorsActive, not recruitingEnd-Stage Renal DiseaseKorea, Republic of
-
Medtronic - MITGCompletedEnd-stage Renal DiseaseGermany
-
China Medical University HospitalUnknown
-
Guangdong Provincial Hospital of Traditional Chinese...Ministry of Science and Technology of the People´s Republic of ChinaUnknown
-
University of California, San FranciscoCompletedEnd-stage Renal DiseaseUnited States
-
Mark A. LumleyHenry Ford Health SystemCompleted
Clinical Trials on Quality of Life Therapy
-
Tumor Center RegensburgGerman Cancer AidCompletedQuality of Life | Breast Cancer | Breast NeoplasmsGermany
-
Sidney Kimmel Cancer Center at Thomas Jefferson...RecruitingGlioblastoma | WHO Grade III Glioma | WHO Grade II GliomaUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedDepression | Pain | Fatigue | Sleep Disorder | Anxiety | Breast Carcinoma | Lung Carcinoma | Alopecia | Colorectal Carcinoma | Nausea and Vomiting | Weight Change | Cognitive Side Effects of Cancer Therapy | Psychological Impact of CancerUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); National...CompletedLymphoma | Plasma Cell MyelomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnCancer SurvivorUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingDyspnea | Malignant NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)TerminatedLymphedema | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Stage III Vulvar Cancer | Stage IVB Vulvar Cancer | Stage 0 Cervical Cancer | Stage 0 Vulvar Cancer | Stage I Vulvar Cancer | Stage IA Cervical Cancer | Stage IB Cervical... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Unresectable Malignant Neoplasm | Metastatic Neoplasm | Recurrent NeoplasmUnited States
-
Roswell Park Cancer InstituteRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Roswell Park Cancer InstituteWithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States